Background
Approximately 10-20% of childhood acute leukemias, including ~80% of those in infants, involve the mixed lineage leukemia (MLL) gene rearrangements that are associated with poor prognosis (only ~40% survival rate). Therefore, it is urgent to develop a new therapy with high efficacy and minimal side effects.
